101 Therapeutics

Company Overview

Snapshot

Founded in November 2020 by Alec Goldberg and James Goldberg, 101 Therapeutics operates with 1-10 employees. The company has secured funding across one round from one investor, Awz Ventures. In April 2023, the company received a Seed round.

Business overview

101 Therapeutics is a Health Tech & Life Sciences company focused on developing cures for multiple infectious diseases. The company has engineered the first targeted glucocorticoid designed to offer the potency of steroids without systemic toxicities. By targeting the host immune system rather than specific pathogens, this technology aims to effectively treat a wide range of infectious diseases, including viral, parasitic, and bacterial infections. The company operates within the Pharmaceuticals, Life Sciences, and Healthcare & Life Sciences sectors, with a business model focused on B2B interactions.

Strategic signal

In May 2023, 101 Therapeutics signed a Memorandum of Understanding with CSIR-Indian Institute of Chemical Technology (CSIR-IICT) for clinical trials of a new Covid-19 drug. This partnership signifies a critical step in advancing their macrophage-targeting drug conjugate, which is currently in Phase 2 clinical trials, towards market availability for treating Covid-19 and other infections like meningitis. This collaboration validates the potential of their drug development pipeline and signals a strategic move towards commercialization and broader impact in infectious disease treatment.

Company Intelligence Q&A

What is 101 Therapeutics' core technology?

101 Therapeutics has developed a targeted glucocorticoid designed to provide the therapeutic benefits of steroids without the associated systemic toxicities. This technology targets the host immune system to treat various infectious diseases.

When was 101 Therapeutics founded and by whom?

101 Therapeutics was founded in November 2020 by Alec Goldberg and James Goldberg.

What significant partnership did 101 Therapeutics establish in May 2023?

In May 2023, 101 Therapeutics signed an MoU with the CSIR-Indian Institute of Chemical Technology (CSIR-IICT) to collaborate on clinical trials for a new Covid-19 drug. CSIR-IICT will serve as the knowledge partner, providing expert guidance and monitoring for the study.

What is the current development stage of 101 Therapeutics' Covid-19 drug?

The Covid-19 drug being developed by 101 Therapeutics is currently in Phase 2 of clinical trials. It is an intravenous macrophage targeting drug conjugate designed to eliminate over-activated macrophages and inactivate the virus.

What is 101 Therapeutics' primary business model?

101 Therapeutics operates with a B2B business model, focusing on interactions with other businesses in the healthcare and life sciences sectors.